Search Results

You are looking at 71 - 80 of 309 items for :

Clear All
Full access

Claire de Oliveira, Joyce Cheng, Kelvin Chan, Craig C. Earle, Murray Krahn and Nicole Mittmann

cancers ( Table 3 ). However, multiple myeloma and pancreatic and liver cancers were overrepresented among HC patients, whereas testicular, thyroid, and cervical cancers and melanoma were overrepresented among NHC patients. Moreover, although most patients

Full access

Ko Maung, Nelson Jen An Chao, Kelly Corbet, Ashley Morris Engemann, Cristina Gasparetto, Mitchell Horwitz, Yubin Kang, Gwynn Douglas Long, Richard D Lopez, David Rizzieri, Stefanie Sarantopoulos, Keith M. Sullivan, Anthony Derek Sung and Taewoong Choi

Background: High-dose melphalan is used in autologous stem cell transplant (auto SCT) for multiple myeloma. Generic melphalan contains Propylene Glycol (PG) as co-solvent. Since FDA approved PG-free melphalan (Evomela ® ) in 2016, there were

Full access

of Primary Central Nervous System Lymphoma El Kamar Francois G. MD Abrey Lauren E. MD 7 2004 2 2 4 4 341 341 349 349 10.6004/jnccn.2004.0028 Multiple Myeloma Clinical Practice Guidelines in Oncology 7 2004 2 2 4 4 350 350 350

Full access

Annual Conference or the NCCN General Poster Session, visit NCCN.org/AC2016 . Updated NCCN Guidelines for Patients and New NCCN Quick Guide for Multiple Myeloma Now Available NCCN has published an updated NCCN Guidelines for Patients: Multiple

Full access

7 7 9 9 What is a Patient Navigator, and Should We Have Them in Major Cancer Centers? Burstein Harold J. MD, PhD 10 2009 7 7 9 9 905 905 905 905 10.6004/jnccn.2009.0060 Multiple Myeloma Anderson Kenneth C. MD Alsina Melissa

Full access

5 5 2 2 Myeloid Growth Factor Guidelines: Moving Toward a Societal Perspective Winn Rodger J. MD 02 2007 5 5 2 2 117 117 117 117 0050117 10.6004/jnccn.2007.0013 Multiple Myeloma Guidelines 02 2007 5 5 2 2 118 118 118 118 0050118 10

Full access

In the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Multiple Myeloma that appeared in the October issue of JNCCN ( JNCCN 2011;9:1146-1183), an error appears in the Lenalidomide as Maintenance Therapy After Autologous SCT

Full access

Joyce LaMori, Kai Zu, Kristina L. Greenwood, Besa Smith, Tyler Smith and Alaina Lee

Background: This study evaluated risk factors predicting unplanned 30-day acute service utilization among adult inpatients subsequent to initial hospitalization for a new diagnosis of leukemia, lymphoma, or myeloma, with a focus on social

Full access

.2011.0093 Surgery for Early-Stage Small Cell Lung Cancer Schneider Bryan J. a MD Saxena Ashish a MD Downey Robert J. b MD 10 2011 9 9 10 10 1132 1132 1139 1139 0091132 10.6004/jnccn.2011.0094 Multiple Myeloma Anderson Kenneth

Full access

Myeloma Principal Investigator: Michaela Liedtke, MD Condition: Multiple myeloma Institution: Stanford University This is an open-label phase I dose-escalation safety study of bortezomib in combination with pralatrexate in patients with